Format

Send to

Choose Destination
See comment in PubMed Commons below
Antimicrob Agents Chemother. 2002 Aug;46(8):2723-6.

Hematologic effects of linezolid: summary of clinical experience.

Author information

  • 1Division of Hematology/Oncology and Ireland Cancer Center, Case Western Reserve University, University Hospitals of Cleveland, 10900 Euclid Avenue, Cleveland, OH 44106-4937, USA. slg5@cwru.edu

Abstract

Linezolid has been associated with reversible myelosuppression. Clinical trial data were evaluated for anemia, thrombocytopenia, and neutropenia. Thrombocytopenia and a slight increased risk for anemia were evident at > or =2 weeks of linezolid treatment. Hematologic abnormalities were consistent with mild, reversible, duration-dependent myelosuppression. Appropriate monitoring is warranted with linezolid use.

PMID:
12121967
PMCID:
PMC127358
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center